Genta slashes workforce and sees revenues tumble
This article was originally published in Scrip
Executive Summary
Genta has cut 30% of its staff after its novel antisense lead drug candidate Genasense (oblimersen sodium) failed to meet one of its primary endpoints in a pivotal Phase III trial earlier this month.